1	Modifiable Risk Factors for Stroke, Dementia, and Late-Life Depression: A Systematic Review
2	and DALY Weighted Risk Factors for a Composite Outcome
3	
4	Jasper R. Senff, MD <sup>1-5</sup> ; Reinier W.P. Tack, MD <sup>1-5</sup> , Akashleena Mallick, MD <sup>1-4</sup> , Leidys Gutierrez-
5	Martinez, MD MSc <sup>1-4</sup> , Jonathan Duskin MD <sup>1-4,14</sup> , Tamara N. Kimball MD <sup>1-4</sup> , Zeina Chemali MD
6	MPH <sup>1,2,6</sup> , Amy Newhouse MD <sup>1,7</sup> , Christina Kourkoulis BS <sup>1-4</sup> , Cyprien Rivier MD <sup>8,9</sup> , Guido J Falcone
7	MD ScD MPH <sup>8,9,</sup> , Kevin N Sheth MD PhD <sup>8,9,</sup> , Ronald M Lazar MD PhD <sup>10</sup> , Sarah Ibrahim RN PhD <sup>11-</sup>
8	<sup>12</sup> , Aleksandra Pikula MD <sup>13-15</sup> , Rudolph E. Tanzi <sup>1</sup> PhD, Gregory Fricchione MD PhD <sup>1,16</sup> , H. Bart
9	Brouwers MD PhD <sup>5</sup> , Gabrël J.E. Rinkel MD PhD FRCP Edin <sup>5</sup> , Nirupama Yechoor MD <sup>1-4</sup> , Jonathan
10	Rosand, MD MSc <sup>1-4</sup> ; Christopher D. Anderson* MD MMsc <sup>1-4,16</sup> , Sanjula D. Singh*, MD PhD MSc <sup>1-5</sup>
11	
12	Affiliations:
13	1. Henry and Allison McCance Center for Brain Health, Massachusetts General Hospital, Boston,
14	MA, USA
15	2. Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
16	3. Broad Institute of MIT and Harvard, Cambridge, MA, USA
17	4. Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
18	5. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical
19	Center Utrecht, Utrecht, NL
20	6. Division of Neuropsychiatry, Massachusetts General Hospital, Boston, MA, United States
21	7. Department of Medicine, Massachusetts General Hospital, Boston, MA, United States,
22	8. Department of Neurology, Yale School of Medicine, New Haven, CT, USA
23	9. Yale Center for Brain and Mind Health, Yale School of Medicine, New Haven, CT, USA
24	10. McKnight Brain Institute, Department of Neurology, School of Medicine, University of Alabama
25	School of Medicine, Birmingham, AL, United States
26	11. Program for Health System and Technology Evaluation, Toronto General Hospital Research
27	Institute, Department of Neurology, Toronto Western Hospital
28	12. Centre for Advancing Collaborative Healthcare & Education (CACHE), University of Toronto

- 29 13. Department of Medicine (Neurology), University of Toronto, Toronto, ON, Canada,
- 30 14. Jay and Sari Sonshine Centre for Stroke Prevention and Cerebrovascular Brain Health, Krembil
- 31 Brain Institute, University Health Network, Toronto, ON, Canada
- 32 15. Lawrence S Bloomberg Faculty of Nursing, University of Toronto, Toronto, ON, Canada
- 33 16. Department of Neurology, Brigham and Women's Hospital, Boston, MA, USA
- 34 \* Contributed equally to this manuscript.
- 35 Running head: Modifiable Risk Factors for Brain Disease
- **36 Corresponding author:**
- 37 Sanjula Dhillon Singh
- Email address: ssingh32@mgh.harvard.edu
- 39 Address: McCance Center for Brain Health, Massachusetts General Hospital, Harvard
- 40 Medical School, 399 Revolution Drive, Sommerville, MA 02145, United States of America
- 41

42	Title character count:	146	No. of references:	159
43	Word count abstract:	250	No. of tables:	2 (7 supplementary)
44	Word count article:	3493	No. of figures:	4 (1 supplementary)

#### Abstract

47 Background: At least 60% of stroke, 40% of dementia, and 35% of late-life depression (LLD) are
48 attributable to modifiable risk factors, with great overlap due to a shared underlying pathophysiology.
49 This study aims to systematically identify overlapping risk factors for these diseases and calculate
50 their relative impact on a composite outcome.

51 Methods: A systematic literature review was performed in Pubmed, Embase, and PsycInfo, between 52 January 2000 and September 2023. We included meta-analyses reporting effect sizes of modifiable 53 risk factors on the incidence of stroke, dementia, and/or LLD. The most relevant meta-analyses were 54 selected, and Disability Adjusted Life Year (DALY) weighted beta-coefficients were calculated for a 55 composite outcome. The beta-coefficients were then normalized to assess relative impact.

Results: Our search yielded 182 meta-analyses meeting the inclusion criteria, of which 59 were
selected to calculate DALY-weighted risk factors for a composite outcome. Identified risk factors
included alcohol use (normalized beta-coefficient highest category: -20), blood pressure (87), BMI
(42), fasting plasma glucose (57), total cholesterol (14), leisure time cognitive activity (-54),
depressive symptoms (34), diet (27), hearing loss (35), kidney function (60), pain (25), physical
activity (-34), purpose in life (-30), sleep (44), smoking (58), social engagement (32), and stress (32).

62 Discussion: This study identified overlapping modifiable risk factors and calculated the relative 63 impact of these factors on the risk of a composite outcome of stroke, dementia, and LLD. These 64 findings could guide preventative strategies and serve as an empirical foundation for future 65 development of tools that can empower people to reduce their risk of these diseases.

66

67 Funding: US National Institutes of Health and American Heart Association.

68

## Introduction

69 Neurological disorders are the leading cause of disability-adjusted life years (DALYs) worldwide<sup>1</sup>. 70 This is largely contributed by stroke (>143 million DALYs), dementia (>25 million DALYs), and 71 depression  $(>37 \text{ million DALYs})^2$ . Research indicates that at least 60% of strokes, 40% of dementia, 72 and 35% of late-life depression (LLD) cases could be prevented or slowed down toward the limit of human life span through adequate risk factor  $control^{3-6}$ . Epidemiological studies demonstrate that risk 73 74 factors such as blood pressure, blood sugar, cholesterol, diet, body mass index (BMI), physical 75 activity, smoking, and social isolation are shared among these age-related brain diseases<sup>1,7-10</sup>. This 76 overlap in risk factors is, at least partially, attributable to the shared underlying pathophysiology of 77 neurodegenerative and cerebrovascular disease, including cerebral small vessel disease (CSVD) -78 with multifaceted impact on cerebral circulation and brain integrity<sup>11,12</sup>.

79

80 Evidence-based tools, such as models or scores, can empower, educate, and motivate both patients 81 and practitioners to facilitate behavioral changes that reduce modifiable risk factors for age-related brain diseases<sup>13</sup>. However, the currently available tools that address modifiable risk factors have 82 83 limitations. Most existing tools for dementia, stroke, and LLD mostly focus on risk stratification of 84 individual brain diseases <sup>14–23</sup> or together with cardiovascular disease<sup>10</sup>, lacking a holistic approach 85 that addresses the shared underlying pathophysiology. In line with the recommendations of the American Heart Association (AHA) and the American Academy of Neurology (AAN)<sup>10,24,25</sup>, there is a 86 87 need to develop, optimize, and implement novel and practical tools that address modifiable risk 88 factors to substantiate preventive neurology in both primary care and specialized medical care 89 worldwide.

90

While there are overlapping risk factors for stroke, dementia, and LLD, these factors have varying
impacts on each disease<sup>1,7-10</sup> To develop effective tools for addressing age-related brain diseases
holistically, it is crucial to first understand how overlapping risk factors differentially impact the

- 94 incidence and burden (expressed in DALYs) of these diseases, which is currently a gap in the
- 95 available literature.
- 96 Therefore, this study aims to identify overlapping risk factors, obtain the most relevant effect sizes,
- 97 and calculate their DALY-weighted effect on a composite outcome of stroke, dementia, and LLD.

# 98 **Methods** 99 100 Study design 101 The study design, registered in PROSPERO (identifier: CRD42023476939), is illustrated in Figure 1. 102 The systematic review of the literature was conducted in line with the Joanna Briggs Institute and 103 PRISMA guidelines<sup>26,27</sup>. The search design was based on a PEO (Population, Exposure, Outcome) 104 format<sup>28</sup>. 105 106 Systematic review of risk models: identifying overlapping risk factors 107 One authors (JRS) searched PubMed and Embase from January 2000 to July 2023 (Table S1). 108 Inclusion criteria were: (i) indexed reviews, guidelines, development, and validation studies, (ii)

studies describing risk models for stroke, dementia, and/or LLD, (ii) models validated with a

predictive value with a c-statistic of  $\ge 0.70^{29}$ , and (iii) models including modifiable risk factors. We

included the most recently validated iteration of any model. Exclusion criteria were: (i) models made

for a disease-specific population (e.g., stroke risk in patients with atrial fibrillation) and (ii) machine

learning models<sup>30</sup>. Data extraction included author, publication year, model details, cohort details,

statistical analysis, risk factors, and outcomes. We selected modifiable risk factors overlapping in at

115 116

109

110

111

112

113

114

# 117 Systematic review of meta-analyses: obtaining effect sizes of individual diseases per risk factor

least two diseases for the systematic review of meta-analyses.

118

119 <u>Search strategy</u>

A search was conducted in PubMed, Embase, and PsycInfo between January 2000 and September 2023, by two authors: JRS and RWPT (Table S2). Included exposures were the modifiable risk factors previously identified. The outcomes were defined as the incidence of all cause-dementia (including Alzheimer's disease, vascular dementia, and/or all dementia), stroke (including both

ischemic and hemorrhagic stroke) and/or LLD. Both authors performed title and abstract screening
and full-text analyses independently from each other. Disagreements were resolved in a consensus
meeting with a third reviewer (SDS). The study selection was performed using Covidence (Covidence
Systematic Review Software Veritas Health Innovation, Melbourne, Australia)<sup>31</sup>.

128

# 129 Inclusion- and exclusion criteria

130 The inclusion criteria were: (i) meta-analyses of observational studies, (ii) written in English, (iii) 131 describing a disease-risk factor relationship expressed as an effect size (Relative Risk [RR], Odds 132 Ratio [OR] or Hazard Ratio [HR]), and (iv) risk factors defined as a dichotomized or categorical 133 variable. Restriction to meta-analyses ensured a well-powered and feasible overview of the current 134 literature<sup>32</sup>, while restriction to dichotomized or categorized ensured clinical applicability<sup>33</sup>. For the 135 dietary components, we included factors as stated (either recommended or contraindicated) by the 136 AHA and the Dietary Approaches to Stop Hypertension (DASH)<sup>10,34</sup>. Our exclusion criteria included: 137 (i) disease-specific populations (e.g., patients with atrial fibrillation) (ii) treatments (e.g., cholesterol 138 levels in statin treatment), and (iii) composite outcomes (e.g., cardiovascular disease instead of stroke) 139 or subtypes of the outcomes (e.g., ischemic stroke only).

140

# 141 Data extraction

142 Data extract was performed by one of two authors, JRS and RWPT. Extracted data included first 143 author, year of publication, exposure definition, outcome definition, effect size including 95% 144 confidence interval (CI), number of included studies in meta-analyses, total sample size, number of 145 outcomes, level of heterogeneity (I<sup>2</sup>), risk of bias (ROB) tool (e.g., Newcastle-Ottawa Scale), ROB 146 assessment, and publication bias (Egger's test, Begg's test, funnel plot).

147

## 148 <u>Study selection to identify the most relevant effect sizes</u>

Study selection to identify the most relevant effect sizes was performed by two authors (JRS and RWPT) individually. Disagreements were resolved in a consensus meeting. For each factor, the most recent meta-analysis was included. Exceptions were made if an earlier meta-analysis had a sample

152	size at least 20% larger. If two meta-analysis had similar sample size selection was based on a								
153	difference in quality assessed through heterogeneity level, ROB assessment, and publication bias. The								
154	initial selection was based on studies that reported RR. If no studies reporting RR were available,								
155	studies reporting HR, or if not available OR, were selected.								
156									
157	DALY weighted risk factors for a composite outcome								
158	Risk factor definition								
159	Risk factors cut-offs aligned with the AHA guidelines and Life's Essential 8 where available <sup>10</sup> .								
160									
161	Statistical Analysis								
162	Table S4 shows the statistical methodology. To standardize effect sizes and corresponding 95%								
163	confidence interval (CI) we transformed HR and OR to RR based on the disease-specific incidence								
164	rates $(r)^{35}$ . We obtained disease-specific DALYs using the most recent incidence rates from the Global								
165	Burden of Disease study 2019 : "Stroke" (157.99 per 100,000), "Alzheimer diseases and other related								
166	dementias" (93.52 per 100,000), and "Major Depressive Disorder" (3551.60 per 100,000) <sup>2</sup> . To								
167	calculate weighted effect size for a composite outcome of stroke, dementia, and LLD, the relative								
168	risks with corresponding 95% CI for each risk factor category were weighted according to their								
169	attributed burden, expressed in DALYs (stroke: 5.654%, dementia: 0.997%, LLD: 1.461%) <sup>2</sup> . If there								
170	was no effect size for a certain disease-risk factor relationship, the disease was not included in the								
171	weighting. The relative risks that remained significant after calculating the composite effect size were								
172	log transferred into beta ( $\beta$ ) coefficients. To enhance interpretation and assess the relative impact of								
173	the risk factors on a composite outcome, we normalized the beta-coefficient. The lowest $\beta$ -coefficient								
174	was normalized to 1, scaling all other $\beta$ -coefficients by the same factor <sup>15</sup> .								

175	Results
176	
177	Systematic review of risk models: Identification of overlapping modifiable risk factors
178	In total, 37 articles describing 54 risk models met inclusion criteria (Figure S1). Of the models, 36
179	(67%) were on stroke, 16 (30%) on dementia, and two (4%) for LLD; none addressed a composite
180	outcome. Table S4 provides an overview of the included models The models identified 18
181	modifiable factors that overlapped in at least two outcomes: (1) alcohol consumption, (2) blood
182	pressure, (3) body mass index (BMI), (4) blood sugar, (5) cholesterol, (6) cognitive activity, (7)
183	depressive symptoms, (8) diet, (9) hearing impairment, (10) kidney function, (11) pain, (12) physical
184	activity, (13) self-rated health, (14) sense of belonging, (15) sleep, (16) smoking, (17) social
185	engagement, and (18) stress.
400	

186

187

Systematic review of meta-analyses: obtaining effect sizes of individual diseases per risk factor
Subsequently, our systematic review of meta-analyses yielded 182 articles that met our predefined
criteria, encompassing 426 effect sizes (stroke N=260 [61%], dementia N=157 [37%], LLD N=9
[2%]) on 17 modifiable risk factors (Figure 2). Reported effect size metrics were RRs (N=280 [66%]),
HRs (N=111 [26%]) and ORs (N=35 [8.2%]). All studies that met our criteria are publicly available at
https://www.zotero.org/groups/5402286/sroma/collections/PY6XGESM.

194

195 <u>Overview of meta-analyses</u>

196

197 Alcohol

Seven meta-analyses described alcohol intake as a risk factor. For stroke incidence, effect sizes ranged from 0.80 (95%CI:0.72-0.90) – 0.89 (95%CI:0.76-1.06) for low alcohol intake (<15 gr/day), 0.79 (95%CI:0.69-0.91) – 1.10 (95%CI:0.97-1.24) for moderate alcohol intake (15-30 gr/day), and 1.19 (95%CI:0.93-1.52) – 1.64 (95%CI:1.39-1.93) for heavy alcohol intake (>30 gr/day) (reference no alcohol intake)<sup>36-40</sup>. For dementia incidence, effect sizes ranged from 0.74 (95%CI:0.61-0.91) – 0.75

203	(95%CI:0.51-1.11	) for low-, 0.58	(95%CI:0.38-0.90)	) - 0.74 (	(95%CI:0.61-0.91	) for moderate-,	and
-----	------------------	------------------	-------------------	------------	------------------	------------------	-----

- 204 1.00 (95%CI:0.39-2.59) 1.84 (95%CI:1.01-3.34) for heavy alcohol intake<sup>41,42</sup>. No meta-analyses
- 205 were found that assessed the relationship between alcohol intake and LLD incidence.
- 206
- 207 Blood Pressure
- Twelve meta-analyses described blood pressure as a risk factor. For stroke incidence, effect sizes
  ranged from 1.22 (95%CI:0.95-1.57) 1.66 (95%CI:1.51-1.81) for low pre-hypertension (120-
- 210 129/80-84mmHg), 1.79 (95%CI:1.49-2.16) 1.95 (95%CI:1.73-2.21) for high pre-hypertension (130-
- 211 139/85-80 mmHg) and 2.23 (95%CI:2.01-2.48) 10.92 (95%CI:7.07-16.86) for hypertension
- 212 (>140/90 mmHg) (reference blood pressure < 120/80 mmHg)<sup>36,43-48</sup>. For dementia incidence, effect
- 213 sizes for hypertension ranged from 0.98 (95%CI:0.72-1.33) 1.41 (95%CI:1.23-1.62)<sup>49-52</sup>. No meta-
- analyses were found that assessed the relationship blood pressure and LLD incidence.
- 215

## 216 Body Mass Index

- Fifteen meta-analyses described BMI as a risk factor. For stroke incidence, the effect size for
  underweight (<18.5 kg/m<sup>2</sup>) was 0.93 (95%CI:0.82-1.06), for overweight (25-29.9 kg/m<sup>2</sup>) it ranged
- 219 from 1.18 (95%CI:0.98-1.42) 2.01 (95%CI:1.65-2.47), and for obesity ( $\geq$ 30kg/m<sup>2</sup>) it ranged from
- 220 1.16 (95%CI:1.01-1.35) 1.47 (95%CI:1.02-2.11) (reference BMI ranging 18.5-25kg/m<sup>2</sup>)<sup>36,47,48,53,54</sup>.
- For dementia incidence, the effect sizes for underweights ranged from 0.92 (95%CI:0.74-0.92) 1.42
- 222 (95%CI:1.12-1.80), for overweight from 0.82 (95%CI:0.74-0.92) 1.26 (95%CI:1.1-1.44), and for
- 223 obesity from 0.78 (95% CI:0.70-0.86) 1.79 (95% CI:1.31-2.41)<sup>50,51,55-62</sup>. No meta-analyses were found
- that assessed the relationship BMI and LLD incidence.
- 225
- 226 Blood Sugar

227 Six meta-analyses described blood sugar as a risk factor. For stroke incidence, effect sizes ranged

- 228 from 1.08 (95%CI:0.94-1.23) 1.21 (95%:1.02-1.44) for prediabetic blood sugar levels (fasting
- 229 plasma glucose [FPG] 100-126 mg/dL), and from 1.79 (95%CI:1.68-1.91) -2.15 (95%CI:1.76-2.63)
- for diabetic blood sugar levels (FPG >126 mg/dL) (reference FPG <100 mg/dL)<sup>36,63-65</sup>. For dementia

231	incidence, effect sizes ranged from $0.72$ (95%CI: $0.56-0.92$ ) -1.22 (95%CI: $1.06-1.41$ ) for prediabetic
232	blood sugar levels, and from 1.21 (95%CI:1.06-1.37) - 1.49 (95%CI:1.10-2.03) for diabetic blood
233	sugar levels <sup>51,66</sup> . No meta-analyses were found that assessed the relationship blood sugar and LLD
234	incidence.

235

~~ 4

236 Cholesterol

Fifteen meta-analyses described cholesterol as a risk factor. For stroke incidence, effect sizes ranged
from 0.99 (95%CI:0.87-1.12) – 1.14 (95%CI:1.03-1.27) for high total cholesterol, and was 1.09
(95%CI:0.85-1.39) for low-density lipoprotein (LDL) (reference lowest quartiles cholesterol
level)<sup>36,43,47,48,67-71</sup>. For dementia incidence, effect sizes ranged from 1.03 (95%CI:0.74-1.43) – 1.82
(95%CI:1.27-2.6) for high total cholesterol<sup>50,51,56,72,73</sup>. For LLD, the effect size for the presence of
dyslipidemia was 1.08 (95%CI:0.91-1.28)<sup>74</sup>.

243

244 *Cognitive activity* 

245 One meta-analysis described cognitive activity as a risk factor for dementia incidence, with an effect

size of 0.61 (95%CI:0.42-0.90) (reference no cognitive activity)<sup>75</sup>. No meta-analyses were found that

assessed the relationship cognitive activity and stroke or LLD incidence.

248

249 *Depressive symptoms* 

One meta-analysis described depressive symptoms as a risk factor for stroke incidence, with an effect
 size of 1.36 (95%CI1.13-1.51) (reference no depressive symptoms)<sup>76</sup>. No meta-analyses were found
 that assessed the relationship depressive symptoms and dementia or LLD incidence.

253

254 Diet

For stroke, a meta-analysis was included for all 11 dietary components<sup>77–87</sup>. For dementia, metaanalyses for dairy, fish, sugar-sweetened beverages and saturated fats intake were retrieved and included<sup>88–91</sup>. No meta-analyses were found that assessed the relationship diet and LLD incidence.

258

## 259 *Hearing loss*

- 260 Three meta-analyses described hearing loss as an risk factor. The effect size was 1.33 (95%CI:1.18-
- 261 1.49) for stroke<sup>92</sup>, 1.59 (95%CI:1,37-1.86) for dementia<sup>93</sup>, and 1.47 (95%CI:1.31-1.65) for LLD
- **262** incidence (reference no hearing  $loss)^{94}$ .
- 263
- 264 *Kidney Function*

Four meta-analyses described kidney function as a risk factor. For stroke incidence, the effect size ranged from 1.07 (95%CI:0.98-1.17) - 1.10 (95%CI:1.03-1.19) for mild-, was 1.43 (95%CI:1.33-1.54) for moderate- (eGFR 30-60mL/min/1.73m<sup>2</sup>) and 1.70 (95%CI:1.47-1.96) for severe kidney disease (eGFR <30mL/min/1.73m<sup>2</sup>) (reference eGFR  $\geq$ 90mL/min/1.73min2)<sup>36,95,96</sup>. For dementia incidence, the effect size was 1.14 (95%CI:1.06-1.22) for mild-, 1.31 (95%CI:0.92-1.87) for moderate-, and 1.91 (95%CI:1.21-3.01) for severe kidney disease<sup>97</sup>. No meta-analyses were found that assessed the relationship depressive symptoms and LLD incidence.

272

273 Pain

One meta-analysis described the pain as a risk factor for dementia incidence, with an effect size of
1.26 (95%CI:1.18-1.35) (reference no pain)<sup>98</sup>. No meta-analyses were found that assessed the
relationship pain and stroke or LLD incidence.

277

278 *Physical activity* 

Eleven meta-analyses described physical activity as a risk factor. For stroke incidence, effects sizes for a moderate level of physical activity ranged from 0.64 (95%CI:0.48-.0.87) – 0.85 (95%CI:0.78-0.93), and was 0.73 (0.67-0.79) for a high level of physical activity (reference low level of physical activity)  $^{43,99-101}$ . For dementia incidence, effect sizes for a moderate level of physical activity ranged from 0.76 (95%CI:0.61-0.94) – 0.80 (95%CI:0.67-0.94), and from 0.63 (95%CI:0.45-0.89) – 0.80 (95%CI:0.77-0.84) for a high level of physical activity<sup>51,101-106</sup>. No meta-analyses were found that assessed the relationship physical activity and LLD incidence.

286

## 287 *Purpose in life*

Three meta-analyses described purpose in life as a risk factor for dementia<sup>107–109</sup>, with effect sizes ranging from 0.76 (95%CI:0.72-0.79) – 0.81 (95%CI:0.78-0.85) (reference no purpose in life)<sup>107–109</sup>. No meta-analyses were found that assessed the relationship purpose in life and stroke or LLD incidence.

292

293 Sleep

294 Fourteen meta-analyses described sleep as a risk factor. For stroke incidence, the effect sizes of short 295 sleep ( $\leq 6$  hours) ranged from 1.00 (95%CI:0.97-1.24) – 1.71(95%CI:1.39-2.02), for long sleep ( $\geq 8$ 296 hours) it ranged from 1.12 (95%CI:1.01-1.24) – 2.12 (95%CI:1.51-2.73), and for insomnia the effect 297 size was 1.55 (95%CI:1.39-1.72) (reference 6-8 hours of sleep)<sup>36,110-117</sup>. For dementia incidence, the 298 effect size for long sleep was 1.77 (95%CI:1.32-2.37), for short sleep 1.20 (95%CI:0.91-1.59), for 299 insomnia it ranged 1.17 (95%CI 0.95-1.43) - 1.53 (95%CI:1.07-2.18), and for sleep disturbance, it 300 was 1.19 (95%CI1.11-1.29)<sup>118-120</sup>. For LLD, the effect sizes for sleep disturbance ranged from 1.2 (95%CI:0.80-1.70) - 1.82 (95%CI:1.69-1.97)<sup>121,122</sup>. 301

302

303 Smoking

Fifteen meta-analyses described smoking as a risk factor. For stroke incidence, the effect sizes ranged from 1.08 (95%CI:1.03-1.13) – 1.30 (95%CI:0.93-1.81) for former smokers, and from 1.31 (95%CI:1.20-1.43) – 1.84 (1.72-.198) for current smokers (reference never smoked)<sup>36,43,47,48,123-126</sup>. For dementia incidence, the effect sizes ranged from 0.99 (95%CI:0.81-1.21) – 1.01 (95%CI:0.96-1.06) for former smokers, and from 1.27 (95%CI:1.02-1.60) – 1.30 (95%CI:1.18-1.45) for current smokers  $^{50,51,56,127-129}$ . For LLD, the effect size for current smoking was 1.35 (95%CI:1.00-1.81)<sup>74</sup>.

310

311 Social Engagement

Seven meta-analyses described social engagement as a risk factor. For stroke incidence, the effect size
for social isolation/loneliness was 1.32 (95%CI:1.04-1.68), and 0.77 (95%CI: 0.57-1.04) for having a
larger social network (reference not being lonely / small social network)<sup>130,131</sup>. For dementia

315	incidence, the effect size for social isolation/loneliness ranged from 1.23 (95%CI:1.16-1.31) - 1.58
316	(95%CI0.80-3.12), and was 0.81 (95%CI:0.74-0.89) for having a larger social network <sup>132-136</sup> . No
317	meta-analyses were found that assessed the relationship social engagement and LLD incidence.
318	
319	Stress
320	Two meta-analyses described stress as a risk factor. For stroke incidence, the effect size was 1.33
321	(95%CI:1.17-1.50) (reference no perceived stress) <sup>137</sup> . For dementia incidence, the effect size was 1.44
322	(95%CI:1.07-1.95) <sup>138</sup> . No meta-analyses were found that assessed the relationship stress and LLD
323	incidence.
324	
325	Study selection to identify the most relevant effect sizes

326 Of 182 meta-analyses that met the inclusion criteria, 59 were selected to calculate DALY-weighted

327 risk factors for a composite outcome. An overview of the selected studies is presented in Table 1, with

328 the reasoning for selection detailed in Table S5. Study characteristics are reported in Table S6.

329

# **330** DALY weighted risk factors for a composite outcome

The calculated DALY weighted effect sizes for each risk factors are presented in Table 2 and Figure (intermediate calculations Table S7). Highest risk of age-related brain disease were found in hypertension, with a normalized beta of 87 and severe kidney disease (eGFR<30 ml/min/1.73m<sup>2</sup>), with a normalized beta of 60. The highest protective effect sizes were found in leisure time cognitive activity, with a normalized beta of -54 and high levels of physical activity with a normalized beta of -34 (Figure 4).

## Discussion

338

This study identified 18 overlapping modifiable risk factors for stroke, dementia, and LLD and calculated their relative impacts on a composite outcome using DALY-weighted beta-coefficients. By analyzing data from two systematic reviews, we weighted these risk factors according to their contribution to the burden of age-related brain diseases. This approach provided a comprehensive understanding of the relative impacts of each risk factor on the risk of a composite outcome of agerelated brain disease.

345

346 When assessing individual components, hypertension was the factor with the highest individual 347 weight. This is mainly attributable to the well-established significant association between stroke and 348 hypertension<sup>3,139</sup>, and is reinforced by our methods' DALY-based weighting system, which assigns greater impact to stroke compared to dementia or LLD<sup>140</sup>. Cholsterol showed limited weight with no 349 350 significant LDL effect. We focused on all strokes, not distinguishing between ischemic and 351 hemorrhagic types, which might have attenuated the effect due to the contradicting impact of 352 cholesterol levels across stroke subtypes<sup>141</sup>. Additionally, excluding meta-analysis on specific 353 treatmens or dose-responses limited available cholesterol studies. We also revealed substantial 354 weights of leisure time cognitive activities, purpose in life, and absence of social isolation. These 355 weights are mainly due to their association with dementia, where reverse causality may play a 356 significant role<sup>142</sup>. Further, long sleep duration emerged as a major risk factor, potentially due to its 357 relationship with possible confounders such as obesity, hypertension, and diabetes or due to reverse 358 causality or confounding by aging. We focused on individual dietary elements as outlined by AHA 359 Life's Essential 8 and the DASH diet. While we did not explore the complex interplay between these 360 dietary components<sup>118,143,144</sup>, there could be an overestimation of the weights of diet if combined in a 361 future tool that builds on the results of our analysis<sup>145</sup>. Furthermore, dietary comparisons were often 362 made between the highest and lowest quartiles, limiting the clinical applicability. Pain showed a 363 significant effect on dementia risk, likely due to the direct effects of pain and the associated reduction in physical activity<sup>98</sup>, as well as possible reverse causality<sup>146</sup>. Finally, depression was included in our 364

analysis not only as an outcome but also as a risk factor due to its bidirectional associations with vascular brain disease <sup>147</sup>. Depressive symptoms showed an increased risk of stroke, which might be due to both immunological and inflammation effects<sup>148</sup>, as well as its association with poor health behaviors such as smoking and physical inactivity<sup>149</sup>. As we did not include disease-specific populations, we did not access the associations of post-stroke and post-dementia depression<sup>150,151</sup>.

370

371 Some limitations should be considered when interpreting our results. First, we only included 372 overlapping risk factors across the three age-related brain diseases, thereby possibly excluding 373 important modifiable risk factors for an individual disease, such as personality attributes and 374 maladaptive thoughts and behaviors for LLD<sup>152</sup>. However, emerging evidence shows similarities in 375 the biological pathology of dementia, stroke, and LLD, particularly due to small vessel disease -376 which subsequently has overlapping modifiable risk factors<sup>3,9,153</sup>. Second, potential interactions 377 between risk factors, such as interactions or collinearity, were not considered<sup>143,154</sup>. Third, variations 378 in definitions across different meta-analyses were encountered during our weighted risk factor 379 calculations, which limited our use of these categorizations. Fourth, the potential for bias (including 380 reverse causality, particularly important for dementia with its extended prodromal stages) and confounding presents a significant challenge and may have influenced the effect sizes<sup>155</sup>. Fifth, we 381 382 limited inclusion criteria to articles written in English. Finally, the limited amount of published meta-383 analyses on LLD risk factors could affect our risk factor weight calculations' overall 384 comprehensiveness, and representativeness.

385

Given the limited meta-analyses on modifiable risk factors for LLD, future research should prioritize producing high-quality meta-analyses in this area. The overlap in modifiable risk factors presents an opportunity to simultaneously reduce the risk of stroke, dementia, and LLD. Developing holistic tools or models that effectively address these factors could facilitate the prevention and management of age-related brain diseases<sup>10,24,25</sup>. This study provided insights into the relative impact of modifiable risk factors, filling a critical gap in the literature necessary for building such comprehensive tools or models. Future research can use our findings as an empirical foundation for building such tools.

Future studies should explore certain areas that our current calculations have not fully resolved, to enhance the development of a tool or model ready for validation. These areas include assessing the utility and feasibility of the findings, which should incorporate an evaluation of social determinants of health, as well as refining the calibration process. These shortcomings could be addressed in a Delphi process<sup>156</sup>, ensuring the development of a comprehensive tool that leverages all available evidence to empower, educate, and motivate patients and practitioners to adopt lifestyle changes and reduce the risk of stroke, dementia, and LLD<sup>13</sup>.

400

# 401 Conclusion

402 In this study, we systematically identified overlapping modifiable risk factors and calculated the 403 relative impact of these factors on the risk of a composite outcome of stroke, dementia, and 404 depression. These findings could guide preventative strategies and could serve as an empirical 405 foundation for future development of tools that can empower people to change modifiable risk factors 406 associated with these diseases.

## Disclosures

C.D.A. receives sponsored research support from the US National Institutes of Health, the American Heart Association, and Bayer AG, and has consulted for ApoPharma. M.C. is supported by the Wellcome Trust [grant number 205339/Z/16/Z]. JR receives sponsored research support from the US National Institutes of Health and the American Heart Association, receives payments for consulting and expert testimony from the National Football League, consulting for Eli Lilly, and has a leadership or fiduciary role at Columbia University and Lancet Neurology. G.F. receives sponsored research support from the National Institute of Mental Health Clinical Global Mental Health Research T32 Fellowship, receives royalties or licenses from Johns Hopkins University Press, University of Chicago Press, Belvoir Press, and the American Psychiatric Press, is on a Data Safety Monitoring Board or Advisory Board of Healthy Hearts Healthy Minds DSMB, is a Board of Directors member at the Rosalynn Carter Institute, and has stock or stock options from Revival Therapeutics Consultant.

#### **Data sharing statement**

This manuscript only utilized previously published data. All data employed in this study, including the intermediate calculations, are comprehensively presented in the supplementary tables accompanying this manuscript. Should there be any inquiries or requests for further clarification regarding the data, please contact the corresponding author.

#### Acknowledgment

Funding: US National Institutes of Health and American Heart Association.

# References

- 1. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol.* 2019;18(5):459-480. doi:10.1016/S1474-4422(18)30499-X
- 2. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019 (GBD 2019). Seattle, United States: Institute for Health Metrics and Evaluation (IHME). Published online 2020.
- 3. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol.* 2021;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0
- 4. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2022 Update: A Report From the American Heart Association. *Circulation*. 2022;145(8):e153-e639. doi:10.1161/CIR.000000000001052
- 5. Zenebe Y, Akele B, W/Selassie M, Necho M. Prevalence and determinants of depression among old age: a systematic review and meta-analysis. *Ann Gen Psychiatry*. 2021;20(1):55. doi:10.1186/s12991-021-00375-x
- Chang SC, Pan A, Kawachi I, Okereke OI. Risk factors for late-life depression: A prospective cohort study among older women. *Prev Med.* 2016;91:144-151. doi:10.1016/j.ypmed.2016.08.014
- 7. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol.* 2021;20(10):795-820. doi:10.1016/S1474-4422(21)00252-0
- Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Psychiatry*. 2022;9(2):137-150. doi:10.1016/S2215-0366(21)00395-3
- 9. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *Lancet*. 2020;396(10248):413-446. doi:10.1016/S0140-6736(20)30367-6
- 10. Lloyd-Jones DM, Allen NB, Anderson CAM, et al. Life's Essential 8: Updating and Enhancing the American Heart Association's Construct of Cardiovascular Health: A Presidential Advisory From the American Heart Association. *Circulation*. 2022;146(5):e18-e43. doi:10.1161/CIR.000000000001078
- 11. Empana JP, Boutouyrie P, Lemogne C, Jouven X, van Sloten TT. Microvascular Contribution to Late-Onset Depression: Mechanisms, Current Evidence, Association With Other Brain Diseases, and Therapeutic Perspectives. *Biological Psychiatry*. 2021;90(4):214-225. doi:10.1016/j.biopsych.2021.04.012
- 12. Cannistraro RJ, Badi M, Eidelman BH, Dickson DW, Middlebrooks EH, Meschia JF. CNS small vessel disease: A clinical review. *Neurology*. 2019;92(24):1146-1156. doi:10.1212/WNL.00000000007654

- 13. Singh SD, Gutierrez-Martinez L, Newhouse A, Sonni A, Chemali Z, Rosand J. Brain health begins with brain care. *Lancet Neurol.* 2022;21(11):961-962. doi:10.1016/S1474-4422(22)00397-0
- Schiepers OJG, Köhler S, Deckers K, et al. Lifestyle for Brain Health (LIBRA): a new model for dementia prevention. *Int J Geriatr Psychiatry*. 2018;33(1):167-175. doi:10.1002/gps.4700
- 15. Anstey KJ, Cherbuin N, Herath PM. Development of a new method for assessing global risk of Alzheimer's disease for use in population health approaches to prevention. *Prev Sci.* 2013;14(4):411-421. doi:10.1007/s11121-012-0313-2
- 16. D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. *Stroke*. 1994;25(1):40-43. doi:10.1161/01.str.25.1.40
- 17. Cattelani L, Murri MB, Chesani F, Chiari L, Bandinelli S, Palumbo P. Risk Prediction Model for Late Life Depression: Development and Validation on Three Large European Datasets. *IEEE J Biomed Health Inform*. 2019;23(5):2196-2204. doi:10.1109/JBHI.2018.2884079
- Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. *BMJ*. 2013;346:f2573. doi:10.1136/bmj.f2573
- 19. Xing X, Yang X, Liu F, et al. Predicting 10-Year and Lifetime Stroke Risk in Chinese Population. *Stroke*. 2019;50(9):2371-2378. doi:10.1161/STROKEAHA.119.025553
- Qiao Q, Gao W, Laatikainen T, Vartiainen E. Layperson-oriented vs. clinicalbased models for prediction of incidence of ischemic stroke: National FINRISK Study. *Int J Stroke*. 2012;7(8):662-668. doi:10.1111/j.1747-4949.2011.00692.x
- 21. Fisher S, Hsu A, Mojaverian N, et al. Dementia Population Risk Tool (DemPoRT): study protocol for a predictive algorithm assessing dementia risk in the community. *BMJ Open.* 2017;7(10):e018018. doi:10.1136/bmjopen-2017-018018
- 22. Barnes DE, Beiser AS, Lee A, et al. Development and validation of a brief dementia screening indicator for primary care. *Alzheimers Dement*. 2014;10(6):656-665.e1. doi:10.1016/j.jalz.2013.11.006
- 23. Huque MH, Kootar S, Eramudugolla R, et al. CogDrisk, ANU-ADRI, CAIDE, and LIBRA Risk Scores for Estimating Dementia Risk. *JAMA Netw Open*. 2023;6(8):e2331460. doi:10.1001/jamanetworkopen.2023.31460
- 24. Rost NS, Salinas J, Jordan JT, et al. The Brain Health Imperative in the 21st Century—A Call to Action. *Neurology*. 2023;101(13):570-579. doi:10.1212/WNL.000000000207739

- 25. Lazar RM, Howard VJ, Kernan WN, et al. A Primary Care Agenda for Brain Health: A Scientific Statement From the American Heart Association. *Stroke*. 2021;52(6):e295-e308. doi:10.1161/STR.0000000000367
- 26. The Joanna Briggs Institute (2014) Joanna Briggs Institute Reviewers' Manual. 2014 Edition, The Joanna Briggs Institute. Http://Joannabriggs.Org/Assets/Docs/Sumari/ReviewersManual-The-Systematic-Review-of-Economic-Evaluation-Evidence-2014\_v2.Pdf.
- 27. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ*. 2021;372:n71.
- 28. Munn Z, Stern C, Aromataris E, Lockwood C, Jordan Z. What kind of systematic review should I conduct? A proposed typology and guidance for systematic reviewers in the medical and health sciences. *BMC Med Res Methodol.* 2018;18(1):5. doi:10.1186/s12874-017-0468-4
- 29. Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. *Epidemiology*. 2010;21(1):128-138. doi:10.1097/EDE.0b013e3181c30fb2
- 30. Rudin C. Stop Explaining Black Box Machine Learning Models for High Stakes Decisions and Use Interpretable Models Instead. *Nat Mach Intell*. 2019;1(5):206-215. doi:10.1038/s42256-019-0048-x
- 31. Covidence Systematic Review Software, Veritas Health Innovation, Melbourne, Australia. Available at Www.Covidence.Org.
- 32. Haidich AB. Meta-analysis in medical research. *Hippokratia*. 2010;14(Suppl 1):29-37.
- Lash TL, Fox MP, MacLehose RF, Maldonado G, McCandless LC, Greenland S. Good practices for quantitative bias analysis. *Int J Epidemiol.* 2014;43(6):1969-1985. doi:10.1093/ije/dyu149
- 34. Filippou CD, Tsioufis CP, Thomopoulos CG, et al. Dietary Approaches to Stop Hypertension (DASH) Diet and Blood Pressure Reduction in Adults with and without Hypertension: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Adv Nutr. 2020;11(5):1150-1160. doi:10.1093/advances/nmaa041
- 35. Shor E, Roelfs D, Vang ZM. The "Hispanic mortality paradox" revisited: Metaanalysis and meta-regression of life-course differentials in Latin American and Caribbean immigrants' mortality. *Social Science & Medicine*. 2017;186:20-33. doi:10.1016/j.socscimed.2017.05.049
- Yuan W, Wu B, Lou M, et al. Identification of Risk Factors for Stroke in China: A Meta-Analysis of Prospective Cohort Studies. *Frontiers in Neurology*. 2022;13 doi:10.3389/fneur.2022.847304
- 37. Zheng YL, Lian F, Shi Q, et al. Alcohol intake and associated risk of major cardiovascular outcomes in women compared with men: a systematic review

and meta-analysis of prospective observational studies. *BMC Public Health*. 2015;15:773. doi:10.1186/s12889-015-2081-y

- Zhang X, Shu L, Si C, et al. Dietary Patterns and Risk of Stroke in Adults: A Systematic Review and Meta-analysis of Prospective Cohort Studies. J Stroke Cerebrovasc Dis. 2015;24(10):2173-2182. doi:10.1016/j.jstrokecerebrovasdis.2015.05.035
- 39. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. *BMJ*. 2011;342:d671. doi:10.1136/bmj.d671
- 40. Reynolds K, Lewis B, Nolen JD, Kinney GL, Sathya B, He J. Alcohol consumption and risk of stroke: a meta-analysis. *JAMA*. 2003;289(5):579-588. doi:10.1001/jama.289.5.579
- 41. Xu W, Wang H, Wan Y, et al. Alcohol consumption and dementia risk: a doseresponse meta-analysis of prospective studies. *Eur J Epidemiol*. 2017;32(1):31-42. doi:10.1007/s10654-017-0225-3
- 42. Anstey KJ, Mack HA, Cherbuin N. Alcohol consumption as a risk factor for dementia and cognitive decline: meta-analysis of prospective studies. *Am J Geriatr Psychiatry*. 2009;17(7):542-555. doi:10.1097/JGP.0b013e3181a2fd07
- 43. Wang J, Wen X, Li W, Li X, Wang Y, Lu W. Risk Factors for Stroke in the Chinese Population: A Systematic Review and Meta-Analysis. *J Stroke Cerebrovasc Dis.* 2017;26(3):509-517. doi:10.1016/j.jstrokecerebrovasdis.2016.12.002
- 44. Lee M, Saver JL, Chang B, Chang KH, Hao Q, Ovbiagele B. Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. *Neurology*. 2011;77(14):1330-1337. doi:10.1212/WNL.0b013e3182315234
- 45. Huang Y, Cai X, Li Y, et al. Prehypertension and the risk of stroke: a metaanalysis. *Neurology*. 2014;82(13):1153-1161. doi:10.1212/WNL.00000000000268
- Han M, Li Q, Liu L, et al. Prehypertension and risk of cardiovascular diseases: A meta-Analysis of 47 cohort studies. *Journal of Hypertension*. 2019;37(12):2325-2332. doi:10.1097/HJH.000000000002191
- 47. Birhanu MM, Zaman SB, Thrift AG, Evans RG, Zengin A. Risk factors for incident cardiovascular events among adults in low- and middle-income countries: A systematic review and meta-analysis of prospective cohort studies. *Prev Med.* 2022;158:107036. doi:10.1016/j.ypmed.2022.107036
- 48. Wu Y, Xiong Y, Wang P, et al. Risk factors of cardiovascular and cerebrovascular diseases in young and middle-aged adults: A meta-analysis. *Medicine (Baltimore).* 2022;101(48):e32082. doi:10.1097/MD.00000000032082

- 49. Ou YN, Tan CC, Shen XN, et al. Blood Pressure and Risks of Cognitive Impairment and Dementia: A Systematic Review and Meta-Analysis of 209 Prospective Studies. *Hypertension*. 2020;76(1):217-225. doi:10.1161/HYPERTENSIONAHA.120.14993
- 50. Li XY, Zhang M, Xu W, et al. Midlife Modifiable Risk Factors for Dementia: A Systematic Review and Meta-analysis of 34 Prospective Cohort Studies. *Curr Alzheimer Res.* 2019;16(14):1254-1268. doi:10.2174/1567205017666200103111253
- 51. Wu J, Xiong Y, Xia X, et al. Can dementia risk be reduced by following the American Heart Association's Life's Simple 7? A systematic review and dose-response meta-analysis. *Ageing Res Rev.* 2023;83:101788. doi:10.1016/j.arr.2022.101788
- 52. Lennon MJ, Lam BCP, Lipnicki DM, et al. Use of Antihypertensives, Blood Pressure, and Estimated Risk of Dementia in Late Life: An Individual Participant Data Meta-Analysis. *JAMA Netw Open.* 2023;6(9):e2333353. doi:10.1001/jamanetworkopen.2023.33353
- 53. Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. *Stroke*. 2010;41(5):e418-26. doi:10.1161/STROKEAHA.109.576967
- 54. Riaz H, Khan MS, Siddiqi TJ, et al. Association Between Obesity and Cardiovascular Outcomes: A Systematic Review and Meta-analysis of Mendelian Randomization Studies. *JAMA Netw Open.* 2018;1(7):e183788. doi:10.1001/jamanetworkopen.2018.3788
- 55. Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and latelife as a risk factor for dementia: a meta-analysis of prospective studies. *Obes Rev.* 2011;12(5):e426-37. doi:10.1111/j.1467-789X.2010.00825.x
- 56. Ford E, Greenslade N, Paudyal P, et al. Predicting dementia from primary care records: A systematic review and meta-analysis. *PLoS One*. 2018;13(3):e0194735. doi:10.1371/journal.pone.0194735
- 57. Qu Y, Hu HY, Ou YN, et al. Association of body mass index with risk of cognitive impairment and dementia: A systematic review and meta-analysis of prospective studies. *Neurosci Biobehav Rev.* 2020;115:189-198. doi:10.1016/j.neubiorev.2020.05.012
- 58. Pedditzi E, Peters R, Beckett N. The risk of overweight/obesity in mid-life and late life for the development of dementia: a systematic review and meta-analysis of longitudinal studies. *Age Ageing*. 2016;45(1):14-21. doi:10.1093/ageing/afv151
- 59. Loef M, Walach H. Midlife obesity and dementia: meta-analysis and adjusted forecast of dementia prevalence in the United States and China. *Obesity (Silver Spring)*. 2013;21(1):E51-5. doi:10.1002/oby.20037

- 60. Danat IM, Clifford A, Partridge M, et al. Impacts of Overweight and Obesity in Older Age on the Risk of Dementia: A Systematic Literature Review and a Meta-Analysis. *J Alzheimers Dis.* 2019;70(s1):S87-S99. doi:10.3233/JAD-180763
- 61. Beydoun MA, Beydoun HA, Wang Y. Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. *Obes Rev.* 2008;9(3):204-218. doi:10.1111/j.1467-789X.2008.00473.x
- Rahmani J, Roudsari AH, Bawadi H, et al. Body mass index and risk of Parkinson, Alzheimer, Dementia, and Dementia mortality: a systematic review and dose-response meta-analysis of cohort studies among 5 million participants. *Nutr Neurosci.* 2022;25(3):423-431. doi:10.1080/1028415X.2020.1758888
- 63. Shi H, Ge Y, Wang H, Zhang Y, Teng W, Tian L. Fasting blood glucose and risk of Stroke: A Dose-Response meta-analysis. *Clin Nutr.* 2021;40(5):3296-3304. doi:10.1016/j.clnu.2020.10.054
- 64. Lee M, Saver JL, Hong KS, Song S, Chang KH, Ovbiagele B. Effect of prediabetes on future risk of stroke: meta-analysis. *BMJ*. 2012;344:e3564. doi:10.1136/bmj.e3564
- 65. Liao HW, Saver J, Yeh HC, et al. Low fasting glucose and future risks of major adverse outcomes in people without baseline diabetes or cardiovascular disease: a systematic review and meta-analysis. *BMJ Open*. 2019;9(7):e026010. doi:10.1136/bmjopen-2018-026010
- 66. Xue M, Xu W, Ou YN, et al. Diabetes mellitus and risks of cognitive impairment and dementia: A systematic review and meta-analysis of 144 prospective studies. *Ageing Res Rev.* 2019;55:100944. doi:10.1016/j.arr.2019.100944
- 67. Banach M, Shekoohi N, Mikhailidis DP, Lip GYH, Hernandez AV, Mazidi M. Relationship between low-density lipoprotein cholesterol, lipid-lowering agents and risk of stroke: a meta-analysis of observational studies (n = 355,591) and randomized controlled trials (n = 165,988). *Archives of Medical Science*. 2022;18(4):912-929. doi:10.5114/aoms/145970
- Qie R, Liu L, Zhang D, et al. Dose-Response Association Between High-Density Lipoprotein Cholesterol and Stroke: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *Prev Chronic Dis.* 2021;18:E45. doi:10.5888/pcd18.200278
- 69. Peters SA, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total cholesterol as a risk factor for coronary heart disease and stroke in women compared with men: A systematic review and meta-analysis. *Atherosclerosis*. 2016;248:123-131. doi:10.1016/j.atherosclerosis.2016.03.016
- 70. Liu Y, Jin X, Fu K, et al. Non-traditional lipid profiles and the risk of stroke: A systematic review and meta-analysis. *Nutr Metab Cardiovasc Dis.* 2023;33(4):698-714. doi:10.1016/j.numecd.2023.01.003

- 71. Wang P, Sun J, Xie T, Lv S. Serum non-high-density lipoprotein cholesterol and risk of stroke in the general population: A meta-analysis. *International Journal of Clinical and Experimental Medicine*. 2018;11(3):1467-1474.
- 72. Zhu Y, Liu X, Zhu R, Zhao J, Wang Q. Lipid levels and the risk of dementia: A dose-response meta-analysis of prospective cohort studies. *Ann Clin Transl Neurol.* 2022;9(3):296-311. doi:10.1002/acn3.51516
- 73. Anstey KJ, Ashby-Mitchell K, Peters R. Updating the Evidence on the Association between Serum Cholesterol and Risk of Late-Life Dementia: Review and Meta-Analysis. *J Alzheimers Dis.* 2017;56(1):215-228. doi:10.3233/JAD-160826
- 74. Valkanova V, Ebmeier KP. Vascular risk factors and depression in later life: a systematic review and meta-analysis. *Biol Psychiatry*. 2013;73(5):406-413. doi:10.1016/j.biopsych.2012.10.028
- 75. Yates LA, Ziser S, Spector A, Orrell M. Cognitive leisure activities and future risk of cognitive impairment and dementia: systematic review and meta-analysis. *Int Psychogeriatr.* 2016;28(11):1791-1806. doi:10.1017/S1041610216001137
- 76. Eurelings LSM, van Dalen JW, Ter Riet G, et al. Apathy and depressive symptoms in older people and incident myocardial infarction, stroke, and mortality: A systematic review and meta-analysis of individual participant data. *Clinical Epidemiology*. 2018;10. doi:10.2147/CLEP.S150915
- 77. Hu D, Huang J, Wang Y, Zhang D, Qu Y. Fruits and vegetables consumption and risk of stroke: a meta-analysis of prospective cohort studies. *Stroke*. 2014;45(6):1613-1619. doi:10.1161/STROKEAHA.114.004836
- Bechthold A, Boeing H, Schwedhelm C, et al. Food groups and risk of coronary heart disease, stroke and heart failure: A systematic review and dose-response meta-analysis of prospective studies. *Crit Rev Food Sci Nutr.* 2019;59(7):1071-1090. doi:10.1080/10408398.2017.1392288
- 79. Hu H, Zhao Y, Feng Y, et al. Consumption of whole grains and refined grains and associated risk of cardiovascular disease events and all-cause mortality: a systematic review and dose-response meta-analysis of prospective cohort studies. *Am J Clin Nutr.* 2023;117(1):149-159. doi:10.1016/j.ajcnut.2022.10.010
- Papp RE, Hasenegger V, Ekmekcioglu C, Schwingshackl L. Association of poultry consumption with cardiovascular diseases and all-cause mortality: a systematic review and dose response meta-analysis of prospective cohort studies. *Crit Rev Food Sci Nutr.* 2023;63(15):2366-2387. doi:10.1080/10408398.2021.1975092
- 81. Mendes V, Niforou A, Kasdagli MI, Ververis E, Naska A. Intake of legumes and cardiovascular disease: A systematic review and dose-response meta-analysis. *Nutr Metab Cardiovasc Dis.* 2023;33(1):22-37. doi:10.1016/j.numecd.2022.10.006

- Shao C, Tang H, Zhao W, He J. Nut intake and stroke risk: A dose-response meta-analysis of prospective cohort studies. *Sci Rep.* 2016;6:30394. doi:10.1038/srep30394
- 83. Wang Y, Zhao R, Wang B, Zhao C, Zhu B, Tian X. The Dose-Response Associations of Sugar-Sweetened Beverage Intake with the Risk of Stroke, Depression, Cancer, and Cause-Specific Mortality: A Systematic Review and Meta-Analysis of Prospective Studies. *Nutrients*. 2022;14(4). doi:10.3390/nu14040777
- 84. Rossi M, Turati F, Lagiou P, Trichopoulos D, La Vecchia C, Trichopoulou A. Relation of dietary glycemic load with ischemic and hemorrhagic stroke: a cohort study in Greece and a meta-analysis. *Eur J Nutr.* 2015;54(2):215-222. doi:10.1007/s00394-014-0702-3
- 85. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. *BMJ*. 2009;339:b4567. doi:10.1136/bmj.b4567
- Kang ZQ, Yang Y, Xiao B. Dietary saturated fat intake and risk of stroke: Systematic review and dose-response meta-analysis of prospective cohort studies. *Nutr Metab Cardiovasc Dis.* 2020;30(2):179-189. doi:10.1016/j.numecd.2019.09.028
- 87. Zhang XW, Yang Z, Li M, Li K, Deng YQ, Tang ZY. Association between dietary protein intake and risk of stroke: A meta-analysis of prospective studies. *Int J Cardiol.* 2016;223:548-551. doi:10.1016/j.ijcard.2016.08.106
- 88. Talebi S, Asoudeh F, Naeini F, Sadeghi E, Travica N, Mohammadi H. Association between animal protein sources and risk of neurodegenerative diseases: a systematic review and dose-response meta-analysis. *Nutr Rev.* 2023;81(9):1131-1143. doi:10.1093/nutrit/nuac114
- Bakre AT, Chen R, Khutan R, et al. Association between fish consumption and risk of dementia: a new study from China and a systematic literature review and meta-analysis. *Public Health Nutr.* 2018;21(10):1921-1932. doi:10.1017/S136898001800037X
- 90. Zhu RZ, Chen MQ, Zhang ZW, Wu TY, Zhao WH. Dietary fatty acids and risk for Alzheimer's disease, dementia, and mild cognitive impairment: A prospective cohort meta-analysis. *Nutrition*. 2021;90:111355. doi:10.1016/j.nut.2021.111355
- 91. Sun Q, Yang Y, Wang X, Yang R, Li X. The Association between Sugar-Sweetened Beverages and Cognitive Function in Middle-Aged and Older People: A Meta-Analysis. *Journal of Prevention of Alzheimer's Disease*. 2022;9(2):323-330. doi:10.14283/jpad.2021.71
- 92. Khosravipour M, Rajati F. Sensorineural hearing loss and risk of stroke: a systematic review and meta-analysis. *Sci Rep.* 2021;11(1):11021. doi:10.1038/s41598-021-89695-2

- Liang Z, Li A, Xu Y, Qian X, Gao X. Hearing Loss and Dementia: A Meta-Analysis of Prospective Cohort Studies. *Frontiers in Aging Neuroscience*. 2021;13. doi:10.3389/fnagi.2021.695117
- 94. Lawrence BJ, Jayakody DMP, Bennett RJ, Eikelboom RH, Gasson N, Friedland PL. Hearing Loss and Depression in Older Adults: A Systematic Review and Meta-analysis. *Gerontologist.* 2020;60(3):e137-e154. doi:10.1093/geront/gnz009
- 95. Lee M, Saver JL, Chang KH, Liao HW, Chang SC, Ovbiagele B. Low glomerular filtration rate and risk of stroke: meta-analysis. *BMJ*. 2010;341:c4249. doi:10.1136/bmj.c4249
- 96. Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. *Nephrol Dial Transplant*. 2015;30(7):1162-1169. doi:10.1093/ndt/gfv009
- 97. Kjaergaard AD, Ellervik C, Witte DR, Nordestgaard BG, Frikke-Schmidt R, Bojesen SE. Kidney function and risk of dementia: Observational study, metaanalysis, and two-sample mendelian randomization study. *Eur J Epidemiol*. 2022;37(12):1273-1284. doi:10.1007/s10654-022-00923-z
- 98. Yuan H, Ahmed WL, Liu M, Tu S, Zhou F, Wang S. Contribution of pain to subsequent cognitive decline or dementia: A systematic review and metaanalysis of cohort studies. *Int J Nurs Stud.* 2023;138:104409. doi:10.1016/j.ijnurstu.2022.104409
- Wendel-Vos GC, Schuit AJ, Feskens EJ, et al. Physical activity and stroke. A meta-analysis of observational data. *Int J Epidemiol.* 2004;33(4):787-798. doi:10.1093/ije/dyh168
- 100. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. *Stroke*. 2003;34(10):2475-2481. doi:10.1161/01.STR.0000091843.02517.9D
- 101. Kivimäki M, Singh-Manoux A, Pentti J, et al. Physical inactivity, cardiometabolic disease, and risk of dementia: an individual-participant meta-analysis. *BMJ*. 2019;365:I1495. doi:10.1136/bmj.I1495
- 102. Xu W, Wang HF, Wan Y, Tan CC, Yu JT, Tan L. Leisure time physical activity and dementia risk: a dose-response meta-analysis of prospective studies. *BMJ Open*. 2017;7(10):e014706. doi:10.1136/bmjopen-2016-014706
- 103. Iso-Markku P, Kujala UM, Knittle K, Polet J, Vuoksimaa E, Waller K. Physical activity as a protective factor for dementia and Alzheimer's disease: systematic review, meta-analysis and quality assessment of cohort and case-control studies. *Br J Sports Med.* 2022;56(12):701-709. doi:10.1136/bjsports-2021-104981
- 104. de Souto Barreto P, Demougeot L, Vellas B, Rolland Y. Exercise Training for Preventing Dementia, Mild Cognitive Impairment, and Clinically Meaningful Cognitive Decline: A Systematic Review and Meta-analysis. J Gerontol A Biol Sci Med Sci. 2018;73(11):1504-1511. doi:10.1093/gerona/glx234

- 105. Lee J. The Relationship Between Physical Activity and Dementia: A Systematic Review and Meta-Analysis of Prospective Cohort Studies. *J Gerontol Nurs*. 2018;44(10):22-29. doi:10.3928/00989134-20180814-01
- 106. Guure CB, Ibrahim NA, Adam MB, Said SM. Impact of Physical Activity on Cognitive Decline, Dementia, and Its Subtypes: Meta-Analysis of Prospective Studies. *Biomed Res Int*. 2017;2017:9016924. doi:10.1155/2017/9016924
- 107. Sutin DAR, Luchetti M, Aschwanden D, Stephan Y, Sesker AA, Terracciano A. Sense of meaning and purpose in life and risk of incident dementia: New data and meta-analysis. *Arch Gerontol Geriatr.* 2023;105:104847. doi:10.1016/j.archger.2022.104847
- 108. Bell G, Singham T, Saunders R, John A, Stott J. Positive psychological constructs and association with reduced risk of mild cognitive impairment and dementia in older adults: A systematic review and meta-analysis. *Ageing Res Rev.* 2022;77:101594. doi:10.1016/j.arr.2022.101594
- 109. Sutin AR, Aschwanden D, Luchetti M, Stephan Y, Terracciano A. Sense of Purpose in Life Is Associated with Lower Risk of Incident Dementia: A Meta-Analysis. *J Alzheimers Dis*. 2021;83(1):249-258. doi:10.3233/JAD-210364
- 110. Wu TT, Zou YL, Xu KD, et al. Insomnia and multiple health outcomes: umbrella review of meta-analyses of prospective cohort studies. *Public Health*. 2023;215. doi:10.1016/j.puhe.2022.11.021
- 111. Wang H, Sun J, Sun M, Liu N, Wang M. Relationship of sleep duration with the risk of stroke incidence and stroke mortality: an updated systematic review and dose-response meta-analysis of prospective cohort studies. *Sleep Med.* 2022;90:267-278. doi:10.1016/j.sleep.2021.11.001
- 112. Li W, Wang D, Cao S, et al. Sleep duration and risk of stroke events and stroke mortality: A systematic review and meta-analysis of prospective cohort studies. *Int J Cardiol.* 2016;223:870-876. doi:10.1016/j.ijcard.2016.08.302
- 113. Leng Y, Cappuccio FP, Wainwright NW, et al. Sleep duration and risk of fatal and nonfatal stroke: a prospective study and meta-analysis. *Neurology*. 2015;84(11):1072-1079. doi:10.1212/WNL.00000000001371
- 114. Jike M, Itani O, Watanabe N, Buysse DJ, Kaneita Y. Long sleep duration and health outcomes: A systematic review, meta-analysis and meta-regression. *Sleep Med Rev.* 2018;39:25-36. doi:10.1016/j.smrv.2017.06.011
- 115. He Q, Sun H, Wu X, et al. Sleep duration and risk of stroke: a dose-response meta-analysis of prospective cohort studies. *Sleep Med.* 2017;32:66-74. doi:10.1016/j.sleep.2016.12.012
- 116. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. *Eur Heart J.* 2011;32(12):1484-1492. doi:10.1093/eurheartj/ehr007

- 117. Ge B, Guo X. Short and long sleep durations are both associated with increased risk of stroke: a meta-analysis of observational studies. *Int J Stroke*. 2015;10(2):177-184. doi:10.1111/ijs.12398
- 118. Fan L, Xu W, Cai Y, Hu Y, Wu C. Sleep Duration and the Risk of Dementia: A Systematic Review and Meta-analysis of Prospective Cohort Studies. *J Am Med Dir Assoc.* 2019;20(12):1480-1487.e5. doi:10.1016/j.jamda.2019.06.009
- 119. de Almondes KM, Costa MV, Malloy-Diniz LF, Diniz BS. Insomnia and risk of dementia in older adults: Systematic review and meta-analysis. J Psychiatr Res. 2016;77:109-115. doi:10.1016/j.jpsychires.2016.02.021
- 120. Shi L, Chen SJ, Ma MY, et al. Sleep disturbances increase the risk of dementia: A systematic review and meta-analysis. *Sleep Med Rev.* 2018;40:4-16. doi:10.1016/j.smrv.2017.06.010
- 121. Bao YP, Han Y, Ma J, et al. Cooccurrence and bidirectional prediction of sleep disturbances and depression in older adults: Meta-analysis and systematic review. *Neurosci Biobehav Rev.* 2017;75:257-273. doi:10.1016/j.neubiorev.2017.01.032
- 122. Hill Almeida LM, Flicker L, Hankey GJ, Golledge J, Yeap BB, Almeida OP. Disrupted sleep and risk of depression in later life: A prospective cohort study with extended follow up and a systematic review and meta-analysis. *Journal of Affective Disorders*. 2022;309. doi:10.1016/j.jad.2022.04.133
- 123. Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. *British Medical Journal.* 1989;298(6676):789-794. doi:10.1136/bmj.298.6676.789
- 124. Peters SA, Huxley RR, Woodward M. Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. *Stroke*. 2013;44(10):2821-2828. doi:10.1161/STROKEAHA.113.002342
- 125. Pan B, Jin X, Jun L, Qiu S, Zheng Q, Pan M. The relationship between smoking and stroke: A meta-analysis. *Medicine (Baltimore)*. 2019;98(12):e14872. doi:10.1097/MD.000000000014872
- 126. Mons U, Müezzinler A, Gellert C, et al. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: metaanalysis of individual participant data from prospective cohort studies of the CHANCES consortium. *BMJ*. 2015;350:h1551. doi:10.1136/bmj.h1551
- 127. Cao L, Tan L, Wang HF, et al. Dietary Patterns and Risk of Dementia: a Systematic Review and Meta-Analysis of Cohort Studies. *Mol Neurobiol.* 2016;53(9):6144-6154. doi:10.1007/s12035-015-9516-4
- 128. Zhong G, Wang Y, Zhang Y, Guo JJ, Zhao Y. Smoking is associated with an increased risk of dementia: a meta-analysis of prospective cohort studies with investigation of potential effect modifiers. *PLoS One*. 2015;10(3):e0118333. doi:10.1371/journal.pone.0118333

- 129. Anstey KJ, von Sanden C, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. *Am J Epidemiol.* 2007;166(4):367-378. doi:10.1093/aje/kwm116
- 130. Valtorta NK, Kanaan M, Gilbody S, Ronzi S, Hanratty B. Loneliness and social isolation as risk factors for coronary heart disease and stroke: Systematic review and meta-analysis of longitudinal observational studies. *Heart*. 2016;102(13):1009-1016. doi:10.1136/heartjnl-2015-308790
- 131. Park JW, Mealy R, Saldanha IJ, et al. Multilevel resilience resources and cardiovascular disease in the United States: A systematic review and metaanalysis. *Health Psychology*. 2022;41(4):278-290. doi:10.1037/hea0001069
- 132. Sommerlad A, Ruegger J, Singh-Manoux A, Lewis G, Livingston G. Marriage and risk of dementia: systematic review and meta-analysis of observational studies. *J Neurol Neurosurg Psychiatry*. 2018;89(3):231-238. doi:10.1136/jnnp-2017-316274
- 133. Qiao L, Wang G, Tang Z, et al. Association between loneliness and dementia risk: A systematic review and meta-analysis of cohort studies. *Frontiers in Human Neuroscience*. 2022;16. doi:10.3389/fnhum.2022.899814
- 134. Kuiper JS, Zuidersma M, Oude Voshaar RC, et al. Social relationships and risk of dementia: A systematic review and meta-analysis of longitudinal cohort studies. *Ageing Res Rev.* 2015;22:39-57. doi:10.1016/j.arr.2015.04.006
- 135. Desai R, John A, Stott J, Charlesworth G. Living alone and risk of dementia: A systematic review and meta-analysis. *Ageing Res Rev.* 2020;62:101122. doi:10.1016/j.arr.2020.101122
- 136. Wang S, Molassiotis A, Guo C, Leung ISH, Leung AYM. Association between social integration and risk of dementia: A systematic review and meta-analysis of longitudinal studies. *J Am Geriatr Soc.* 2023;71(2):632-645. doi:10.1111/jgs.18094
- 137. Booth J, Connelly L, Lawrence M, et al. Evidence of perceived psychosocial stress as a risk factor for stroke in adults: A meta-analysis. *BMC Neurology*. 2015;15(1). doi:10.1186/s12883-015-0456-4
- 138. Franks KH, Bransby L, Saling MM, Pase MP. Association of Stress with Risk of Dementia and Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2021;82(4):1573-1590. doi:10.3233/JAD-210094
- 139. O'Donnell MJ, Chin SL, Rangarajan S, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet.* 2016;388(10046):761-775. doi:10.1016/S0140-6736(16)30506-2
- 140. Seattle, United States: Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2019 (GBD 2019). Global Burden of Disease Collaborative Network.

- 141. Hackam DG, Hegele RA. Cholesterol Lowering and Prevention of Stroke. *Stroke*. 2019;50(2):537-541. doi:10.1161/STROKEAHA.118.023167
- 142. Floud S, Balkwill A, Reeves GK, Peto R, Beral V. Cognitive and social activities and long-term dementia risk Authors' reply. *The Lancet Public Health*. 2021;6(5):e270. doi:10.1016/S2468-2667(21)00072-4
- 143. Mirmiran P, Bahadoran Z, Gaeini Z. Common Limitations and Challenges of Dietary Clinical Trials for Translation into Clinical Practices. *Int J Endocrinol Metab.* 2021;19(3):e108170. doi:10.5812/ijem.108170
- 144. Buxton OM, Marcelli E. Short and long sleep are positively associated with obesity, diabetes, hypertension, and cardiovascular disease among adults in the United States. *Soc Sci Med.* 2010;71(5):1027-1036. doi:10.1016/j.socscimed.2010.05.041
- 145. Salehi-Abargouei A, Maghsoudi Z, Shirani F, Azadbakht L. Effects of Dietary Approaches to Stop Hypertension (DASH)-style diet on fatal or nonfatal cardiovascular diseases--incidence: a systematic review and meta-analysis on observational prospective studies. *Nutrition*. 2013;29(4):611-618. doi:10.1016/j.nut.2012.12.018
- 146. Achterberg W, Lautenbacher S, Husebo B, Erdal A, Herr K. Pain in dementia. *Pain Rep.* 2020;5(1):e803. doi:10.1097/PR9.000000000000803
- 147. Thomas AJ, Kalaria RN, O'Brien JT. Depression and vascular disease: what is the relationship? *J Affect Disord*. 2004;79(1-3):81-95. doi:10.1016/S0165-0327(02)00349-X
- 148. Shimbo D, Chaplin W, Crossman D, Haas D, Davidson KW. Role of depression and inflammation in incident coronary heart disease events. *Am J Cardiol.* 2005;96(7):1016-1021. doi:10.1016/j.amjcard.2005.05.064
- 149. Strine TW, Mokdad AH, Dube SR, et al. The association of depression and anxiety with obesity and unhealthy behaviors among community-dwelling US adults. *Gen Hosp Psychiatry*. 2008;30(2):127-137. doi:10.1016/j.genhosppsych.2007.12.008
- 150. Wijeratne T, Sales C. Understanding Why Post-Stroke Depression May Be the Norm Rather Than the Exception: The Anatomical and Neuroinflammatory Correlates of Post-Stroke Depression. *J Clin Med.* 2021;10(8). doi:10.3390/jcm10081674
- 151. Muliyala KP, Varghese M. The complex relationship between depression and dementia. *Ann Indian Acad Neurol.* 2010;13(Suppl 2):S69-73. doi:10.4103/0972-2327.74248
- 152. Aziz R, Steffens DC. What are the causes of late-life depression? *Psychiatr Clin North Am.* 2013;36(4):497-516. doi:10.1016/j.psc.2013.08.001

- 153. Farhat NS, Theiss R, Santini T, Ibrahim TS, Aizenstein HJ. Neuroimaging of Small Vessel Disease in Late-Life Depression. *Adv Exp Med Biol.* 2019;1192:95-115. doi:10.1007/978-981-32-9721-0\_5
- 154. Diaz KM, Shimbo D. Physical activity and the prevention of hypertension. *Curr Hypertens Rep.* 2013;15(6):659-668. doi:10.1007/s11906-013-0386-8
- 155. Sattar N, Preiss D. Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined? *Circulation*. 2017;135(24):2369-2372. doi:10.1161/CIRCULATIONAHA.117.028307
- 156. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. *J Adv Nurs*. 2000;32(4):1008-1015.
- 157. Zhang C, Qin YY, Chen Q, et al. Alcohol intake and risk of stroke: a doseresponse meta-analysis of prospective studies. *Int J Cardiol.* 2014;174(3):669-677. doi:10.1016/j.ijcard.2014.04.225
- 158. Long J, Duan G, Tian W, et al. Hypertension and risk of depression in the elderly: a meta-analysis of prospective cohort studies. *J Hum Hypertens*. 2015;29(8):478-482. doi:10.1038/jhh.2014.112
- 159. Wang X, Su W, Huang Y, et al. BMI and risk of stroke: a dose-response metaanalysis. *Chinese Journal of Evidence-Based Medicine*. 2022;22(11):1330-1338. doi:10.7507/1672-2531.202205032

## **Figures and tables**

## Figure 1: Study Design









## Figure 3: Effect sizes for stroke, dementia, LLD and a composite outcome.

Abbreviations: BMI: body mass index, dL: deciliter, eGFR: estimated glomerular filtration rate, F: female, FPG: fasting plasma glucose, KG: kilograms, LLD: late-life depression, LDL: low density lipoprotein, M: male, m: meters, mg: milligram, min: minutes, mmHg: millimeters mercury. SSB: sugar sweetened beverages.



Figure 4: Normalized beta-coefficients for a composite outcome

Abbreviations: dL: deciliter, eGFR: estimated glomerular filtration rate, F: female, FPG: fasting plasma glucose, LL: latelife, M: male, m: meters, mg: milligram, ML: midlife min: minutes, mmHg: millimeters mercury.

# Tables

**Table 1:** Selected studies and identification of the most relevant effect size

	Stroke					Dementia					Late-life depression				
lisk factor	Reference	Est.	95% CI	ES	N=	Reference	Est.	95% CI	ES	N=	Reference	Est.	95% CI	ES	N=
Icohol (ref never)				I.		L.					1				
3 standard drinks/day	Zhang <sup>157</sup>	1.20	1.01-1.43	RR	233,689	Xu <sup>41</sup>	1.00	0.39-2.59	RR	73,330	NA	NA	NA	NA	NA
-3 standard drinks/day	Zhang <sup>157</sup>	1.01	0.93-1.09	RR	414,146	Xu <sup>41</sup>	0.58	0.38-0.90	RR	73,330	NA	NA	NA	NA	NA
1 standard drinks/day	Zhang <sup>157</sup>	0.85	0.75-0.95	RR	414,146	Xu <sup>41</sup>	0.75	0.51-1.11	RR	73,330	NA	NA	NA	NA	NA
lood pressure (ref <120/80 mm	nHg)														
140/90 ML	Wang <sup>43</sup>	2.68	2.20-3.26	RR	279,088	Ou <sup>49</sup>	1.20	1.06-1.35	RR	1,320,441	Long <sup>158</sup>	1.16	0.91-1.42	RR	9,647
140/90 LL	Wang <sup>43</sup>	2.68	2.20-3.26	RR	279,088	Ou <sup>49</sup>	1.01	0.96-1.06	RR	57,907	Long <sup>158</sup>	1.16	0.91-1.42	RR	9,647
30-139/ 85-89	Huang <sup>45</sup>	1.95	1.73-2.21	RR	762,393	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
20-129 / 80-84	Huang <sup>45</sup>	1.44	1.27-1.63	RR	762,393	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
MI (ref 18.5-25 kg/m2)															
1L Obese (≥30)	Wang <sup>159</sup>	1.47	1.02-2.11	RR	4,121,082	Qu <sup>57</sup>	1.45	1.19-1.78	RR	41,656	NA	NA	NA	NA	NA
L Obese (≥30)	Wang <sup>159</sup>	1.47	1.02-2.11	RR	4,121,082	Qu <sup>57</sup>	0.78	0.70-0.86	RR	46,472	NA	NA	NA	NA	NA
1L Overweight (25-30)	Wang <sup>159</sup>	1.25	1.16-1.34	RR	3,458,041	Qu <sup>57</sup>	1.22	1.07-1.39	RR	53,690	NA	NA	NA	NA	NA
L Overweight (25-30)	Wang <sup>159</sup>	1.25	1.16-1.34	RR	3,458,041	Qu <sup>57</sup>	0.82	0.74-0.92	RR	32,079	NA	NA	NA	NA	NA
1L Underweight (<18.5)	Wang <sup>159</sup>	0.93	0.82-1.06	RR	3,917,021	Qu <sup>57</sup>	1.42	1.12-1.80	RR	33,992	NA	NA	NA	NA	NA
L Underweight (<18.5)	Wang <sup>159</sup>	0.93	0.82-1.06	RR	3,917,021	Qu <sup>57</sup>	1.23	1.03-1.48	RR	24,556	NA	NA	NA	NA	NA
lood Sugar (ref fasting plasma	glucose < 100 mg/	dL)													
PG (>126)	Shi 63	1.79	1.68-1.91	RR	2,524,770	Xue <sup>66</sup>	1.21	1.06-1.37	RR	2,956,619	NA	NA	NA	NA	NA
PG (100-126)	Shi <sup>63</sup>	1.16	1.11-1.21	RR	2,537,596	Xue <sup>66</sup>	1.22	1.06-1.41	RR	2,956,619	NA	NA	NA	NA	NA
Cholesterol (ref TC/LDL low)															
'C high (Female)	Peters <sup>69</sup>	0.99	0.87-1.12	RR	786,621	Zhu <sup>72</sup>	1.13	1.04-1.22	RR	153,690	Valkanova <sup>74</sup>	1.08	0.99-1.40	OR	17,959
C high (Male)	Peters <sup>69</sup>	1.14	1.03-1.27	RR	786,621	Zhu <sup>72</sup>	1.13	1.04-1.22	RR	153,690	Valkanova <sup>74</sup>	1.08	0.99-1.40	OR	17,959
.DL	Yuan <sup>36</sup>	1.09	0.85-1.39	RR	6676	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Cognitive activity (ref none)															
eisure time cognitive activity	NA	NA	NA	NA	NA	Yates <sup>75</sup>	0.61	0.42-0.90	RR	1,932	NA	NA	NA	NA	NA
Depressive symptoms (ref not p	resent)														
Depressive symptoms	Eurelings <sup>76</sup>	1.36	1.13-1.51	HR	254,694	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Viet (ref low)															
regetables high intake	Hu <sup>77</sup>	0.86	0.79-0.93	RR	932,545	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
ruit high intake	Bechthold <sup>78</sup>	0.83	0.77-0.89	RR	45,806	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Vhole grain high intake	Hu <sup>79</sup>	0.93	0.87-1.00	RR	877,897	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Dairy high intake	Bechthold <sup>78</sup>	0.96	0.90-1.01	RR	452,216	Talebi <sup>88</sup>	0.72	0.58-0.89	RR	2,757	NA	NA	NA	NA	NA
ïsh high intake	Bechthold <sup>78</sup>	0.95	0.89-1.01	RR	409,128	Bakre <sup>89</sup>	0.80	0.74-0.87	RR	40,668	NA	NA	NA	NA	NA
oultry high intake	Papp <sup>80</sup>	0.97	0.87-1.02	RR	1,290,356	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
eans high intake	Mendes <sup>81</sup>	1.00	0.93-1.08	RR	770,735	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Juts high intake	Shao <sup>82</sup>	0.88	0.80-0.97	RR	671,301	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
ed meat high intake	Bechthold <sup>78</sup>	1.16	1.08-1.25	RR	341,767	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
ugar Sweetened Beverage	Wang <sup>83</sup>	1.12	1.03-1.23	RR	350,684	Sun <sup>91</sup>	2.77	2.23-3.43	HR	5,660	NA	NA	NA	NA	NA
weets high intake	Rossi <sup>84</sup>	1.23	1.07-1.41	RR	350,684	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
odium high intake	Strazzullo <sup>85</sup>	1.23	1.06-1.43	RR	147,129	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA

aturated fats high intake	Kang <sup>86</sup>	0.87	0.78-0.96	RR	598,435	Zhu <sup>90</sup>	1.37	0.70-2.69	RR	7,395	NA	NA	NA	NA	NA
rotein high intake	Zhang <sup>87</sup>	0.98	0.89-1.07	RR	528,982	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
fearing loss (ref no loss)															
resence of hearing loss	Khosravipour <sup>92</sup>	1.33	1.18-1.49	HR	5,014,271	Liang <sup>93</sup>	1.59	1.37-1.86	HR	725,847	Lawrence94	1.47	1.31-1.65	OR	147,148
idney function (ref eGFR ≥90 ml/min/1.73 m2)															
GFR <30	Masson <sup>96</sup>	1.70	1.47-1.96	RR	1,743,690	Kjaergaard97	1.91	1.21-3.01	HR	468,699	NA	NA	NA	NA	NA
GFR 30-60	Masson <sup>96</sup>	1.43	1.33-1.54	RR	2,100,733	Kjaergaard97	1.31	0.92-1.87	HR	468,699	NA	NA	NA	NA	NA
GFR 60-90	Masson <sup>96</sup>	1.10	1.03-1.19	RR	861,526	Kjaergaard97	1.14	1.06-1.22	HR	468,699	NA	NA	NA	NA	NA
'ain (ref no pain)	·		·												
ain present	NA	NA	NA	NA	NA	Yuan <sup>98</sup>	1.26	1.18-1.35	OR	1,122,503	NA	NA	NA	NA	NA
'hysical activity (ref low)	·		·												
Ioderate physical activity	Lee <sup>100</sup>	0.80	0.74-0.86	RR	357,791	Iso- Markku <sup>103</sup>	0.80	0.77-0.84	OR	257,983	NA	NA	NA	NA	NA
ligh physical activity	Lee <sup>100</sup>	0.73	0.67-0.79	RR	357,791	Lee <sup>105</sup>	0.77	0.75-0.79	RR	75,447	NA	NA	NA	NA	NA
ense of belonging/ purpose in	n life (ref no purpos	e)	1	1		1		1	1		1			1	-4
urpose in life present	NA	NA	NA	NA	NA	Sutin <sup>107</sup>	0.76	0.72-0.79	HR	202,393	NA	NA	NA	NA	NA
leep (ref 6-8 hours)		1	4												
8 hours of sleep	Jike <sup>114</sup>	1.46	1.26-1.69	RR	542,218	Fan <sup>118</sup>	1.77	1.32-2.37	HR	43,412	NA	NA	NA	NA	NA
6 hours of sleep	He <sup>115</sup>	1.10	0.97-1.24	RR	249,324	Fan <sup>118</sup>	1.20	0.91-1.59	HR	43,412	NA	NA	NA	NA	NA
leep insomnia	Wu <sup>110</sup>	1.55	1.39-1.75	RR	23,312	Shi <sup>120</sup>	1.17	0.95-1.43	RR	226,167	NA	NA	NA	NA	NA
leep problem/disturbance	NA	NA	NA	NA	NA	Shi <sup>120</sup>	1.19	1.11-1.29	RR	246,786	Hill Almeida <sup>122</sup>	1.82	1.69-1.97	RR	54,211
moking		1	4												
ref never)															
Current (Female)	Peters <sup>124</sup>	1.83	1.58-2.12	RR	3,817, 289	Zhong <sup>128</sup>	1.30	1.18-1.45	RR	937,293	Lawrence94	1.35	1.00-1.81	OR	20,120
'urrent (Male)	Peters <sup>124</sup>	1.67	1.49-1.88	RR	3,817, 289	Zhong <sup>128</sup>	1.30	1.18-1.45	RR	937,293	Lawrence94	1.35	1.00-1.81	OR	20,120
ormer (Female)	Peters <sup>124</sup>	1.17	1.12-1.22	RR	3,534,330	Zhong <sup>128</sup>	1.01	0.96-1.06	RR	937,691	NA	NA	NA	NA	NA
ormer (Male)	Peters <sup>124</sup>	1.08	1.03-1.13	RR	3,534,330	Zhong <sup>128</sup>	1.01	0.96-1.06	RR	937,691	NA	NA	NA	NA	NA
ocial engagement (ref not lo	nely, small social net	work)													-
onely / Social isolated	Valtorta <sup>130</sup>	1.32	1.04-1.68	RR	105,514	Wang <sup>136</sup>	1.42	1.26-1.60	RR	83,765	NA	NA	NA	NA	NA
arge social network	Park <sup>131</sup>	0.77	0.57-1.04	RR	23,576	Wang <sup>136</sup>	0.81	0.74-0.89	RR	87,264	NA	NA	NA	NA	NA
tress (no perceived stress)															-
erceived stress	Booth <sup>137</sup>	1.33	1.17-1.50	HR	146,859	Franks <sup>138</sup>	1.44	1.07-1.95	HR	1882	NA	NA	NA	NA	NA

Legend. Abbreviations: CI = Confidence interval, dL = deciliter, eGFR = estimated Glomerulus Filtration Rate, ES = Effect Size, Est = Estimates, HR = Hazard Ratio, Kg = kilograms, LDL = Low Density Lipoprotein, LL = Late-life, mg = milligrams, ML = Midlife, mmHg = millimeters, Hg = mercury, N = number, NA = Not Applicable, OR = Odds Ratio, RR = Relative Risk, TC = total

Variable	Definition	<b>BR (95%CI)</b>	Normalized B
Alcohol	>3 standard drinks/day	1 17 (0.92 - 1.94)	NA
(ref never)	1-3 standard drinks/day	0.93 (0.85-1.01)	NA
()	<1 standard drinks/day	0.73 (0.74-0.93)	-20
Blood pressure	>140/90 ML	2 22 (1 81-2 63)	87
(ref < 120/80  mmHg)	>140/90 LL	2.17 (1.76-2.58)	85
(	130-139/ 85-89	1.95 (1.73-2.21)	73
	120-129 / 80-84	1 44 (1 27-1 63)	40
BMI	ML Obese (>30)	1 47 (1 00-1 93)	42
$(ref 18.5-25 \text{ kg/m}^2)$	LL Obese (>30)	1.34 (0.87-1.80)	NA
	ML Overweight (25-30)	1.25 (1.17-1.33)	24
	LL Overweight (25-30)	1.17 (1.10-1.25)	17
	ML Underweight (<18.5)	0.99 (0.99-1.10)	NA
	LL Underweight (<18.5)	0.97 (0.86-1.08)	NA
Blood sugar	FPG (>126)	1.69 (1.59-1.79)	57
(ref FPG <100mg/dL)	FPG (100-126)	1.17 (1.12-1.22)	17
Cholesterol	TC high (Female)	1.02 (0.92-1.11)	NA
(ref TC/LDL low)	TC high (Male)	1.13 (1.04-1.12)	14
	LDL	1.09 (0.85-1.39)	NA
Cognitive activity (ref none)	Leisure time cognitive activity	0.61 (0.42-0.90)	-54
Depressive symptoms	Present	1.36 (1.13-1.51)	34
(ref not present)		``´´´	
Diet	Vegetables high intake	0.86 (0.79-0.93)	-16
(ref high)	Fruit high intake	0.83 (0.77-0.89)	-20
	Whole grain high intake	0.93 (0.87-1.00)	NA
	Dairy high intake	0.92 (0.87-0.98)	-9
	Fish high intake	0.93 (0.87-0.98)	-8
	Poultry high intake	0.97 (0.87-1.02)	NA
	Beans high intake	1.00 (0.93-1.08)	NA
	Nuts high intake	0.88 (0.80-0.97)	-14
	Red meat high intake	1.16 (1.08-1.25)	16
	Sugar Sweetened Beverage	1.28 (1.16-1.41)	27
	Sweets high intake	1.23 (1.07-1.47)	23
	Sodium high intake	1.23 (1.06-1.43)	23
	Saturated fats high intake	0.93 (0.76-1.10)	NA
	Protein high intake	0.98 (0.89-1.07)	NA
Hearing loss (ref no loss)	Present	1.37 (1.25-1.50)	35
Kidney Function	eGFR <30	1.73 (1.48-1.98)	60
(ref eGFR ≥90 ml/min/1.73	eGFR 30-60	1.41 (1.30-1.53)	38
m2)	eGFR 60-90	1.11 (1.04-1.17)	11
Pain	Present	1.26 (1.18-1.35)	25
(ref no pain)			
Physical activity	Moderate physical activity	0.80 (0.74-0.85)	-25
(ref low)	High physical activity	0.74 (0.68-0.79)	-34
Purpose in life	Present	0.76 (0.72-0.79)	-30
(ref no purpose)			
Sleep	>8 hours of sleep	1.50 (1.30-1.70)	44
(ref 6-8 hours/no problems)	<6 hours of sleep	1.11 (0.99-1.24)	NA
	Sleep insomnia	1.49 (1.33-1.64)	43
	Sleep problem/disturbance	1.41 (1.34-1.49)	38
Smoking	Current (Female)	1.69 (1.48-1.91)	58
(ref never)	Current (Male)	1.58 (1.42-1.73)	50
	Former (Female)	1.14 (1.10-1.19)	15
	Former (Male)	1.07 (1.03-1.11)	7
Social engagement	Lonely / Social isolated	1.33 (1.06-1.61)	32
(ref not lonely/ small social network)	Large social network	0.78 (0.58-0.98)	-28
Stress (ref no perceived stress)	Perceived stress	1.35 (1.17-1.52)	32

# Table 2: DALY weighted effect sizes for a composite outcome

**Legend**. Abbreviations:  $\beta$ : beta-coefficient. CI: Confidence interval, dL: deciliter, eGFR: estimated Glomerulus Filtration Rate, Kg = kilograms, LDL = Low Density Lipoprotein, LL: Late-life, mg: milligrams, ML: Midlife, mmHg: millimeters, Ref: Reference, RR: relative risk, Hg: mercury, NA: Not Applicable, NS: Not Significant, TC: Total Cholesterol.